Needlestick Injury in Healthcare Workers: Complete Step-by-Step Management Guide

PART 1: IMMEDIATE ACTIONS (First 5-10 Minutes)

Step 1 - Wound Decontamination (Do This First, Before Anything Else)

• Needlestick/cut: Remove glove, wash the area thoroughly with soap and water. Do not squeeze, milk, or suck the wound - this does not reduce transmission risk and may increase it.
• Mucous membrane exposure (eye splash): Irrigate copiously with clean water, saline, or sterile irrigant for several minutes.
• Skin (intact or non-intact) splash: Wash thoroughly with soap and water.
• Contact of blood/body fluid with intact, undamaged skin: No further workup needed - intact skin is a complete barrier; this does not constitute an at-risk exposure for HIV, HBV, or HCV.

PART 2: REPORT AND ESCALATE IMMEDIATELY

Step 2 - Report to Occupational Health/Emergency Department

• Report the exposure immediately - time is critical for PEP initiation (< 72 hours for HIV PEP; ideally within 2 hours).
• Contact your institution's Occupational Health Service or go to the Emergency Department if after hours.
• In the US, expert 24/7 consultation is available via the PEPline: 1-888-448-4911 (or http://nccc.ucsf.edu/clinician-consultation/pep-post-exposure-prophylaxis/).
• Document all details: date, time, type of device, depth of injury, visible blood on needle, type of procedure being performed, and source patient information.

PART 3: CHARACTERIZE THE EXPOSURE

Step 3 - Assess the Type and Severity of Exposure

• HIV via needlestick from known HIV+ source: ~0.3% per exposure
• HBV (source HBeAg+, recipient non-immune): 37-62% per exposure - the highest risk
• HCV via needlestick: ~1.8-2% per exposure
• Mucous membrane HIV exposure: ~0.09%
• Intact skin exposure: essentially zero for all three

PART 4: TEST THE SOURCE PATIENT (AND THE EXPOSED HCW)

Step 4 - Source Patient Testing

• HIV: Rapid HIV antigen/antibody combination test (4th generation) - result in ~20 minutes
• HBV: HBsAg (hepatitis B surface antigen) - if unknown status; comprehensive triple screen (HBsAg, HBcAb, HBsAb) is now preferred per 2025 guidelines
• HCV: Anti-HCV antibody ± HCV RNA if antibody positive or if source is high-risk

Step 5 - Baseline Testing of the Exposed Healthcare Worker (HCW)

• HIV antigen/antibody combination test (4th generation)
• HBsAg, anti-HBs, anti-HBc (HBV status)
• Anti-HCV antibody + HCV RNA
• CBC, renal function (creatinine), LFTs (baseline before starting ARVs)
• Pregnancy test if applicable (influences drug selection)

PART 5: SCENARIO-BY-SCENARIO MANAGEMENT

SCENARIO A: SOURCE PATIENT IS HIV-POSITIVE (or Unknown Status)

A1 - Source HIV Status Unknown and Testing Not Possible

• Use shared clinical decision-making to decide whether to initiate PEP.
• Key considerations:
  1. Severity of exposure (large-volume blood, deep percutaneous)
  2. Route of inoculation (hollow-bore needle vs. solid needle)
  3. Epidemiologic likelihood of the source being HIV-positive (e.g., patient from high-prevalence setting, known IVDU, etc.)
• Do not test needles or other sharp instruments for HIV - there is no approved method and results are unreliable.
• Err toward starting PEP in higher-risk scenarios - it can always be stopped if the source tests negative.

When to Initiate HIV PEP

• Yes, start PEP if: high-risk percutaneous exposure (hollow needle with visible blood, deep injury), source is high-risk or known HIV+, or source is unknown in a high-prevalence setting.
• Consider not starting PEP if: exposure was very low-risk (superficial scratch, solid needle, no visible blood), source tests HIV-negative by rapid test, or exposure was with intact skin only.
• Start as soon as possible - within 2 hours is ideal, within 72 hours is the outer limit. PEP started after 72 hours has no proven benefit.

Preferred HIV PEP Regimens (2025 PHS Guidelines)

• If source patient is known to have drug-resistant HIV: consult an HIV expert before selecting a regimen.
• If the HCW is already on PrEP: use shared decision-making - expert consultation is strongly recommended.
• If the HCW is pregnant: certain agents (e.g., efavirenz) should be avoided; consult HIV specialist immediately.

Follow-up Testing After HIV Exposure

• Baseline, then 4-6 weeks, 3 months, and 6 months post-exposure (some centers now follow to 4 months if source is HCV+, due to rare delayed seroconversion).
• If the HCW takes PEP: repeat HIV testing at 4-6 weeks, 3 months, and 6 months.
• If PEP is declined/not indicated: baseline and 6-week testing minimum.

SCENARIO B: HEPATITIS B VIRUS (HBV)

HBV Management Table (from Yamada's Gastroenterology, 7th ed.)

• HBIG should be given within 24 hours of exposure (definitely within 7 days) for maximum benefit.
• Hepatitis D (delta virus) post-exposure recommendations are the same as for HBV (Yamada's Gastroenterology).
• There is no specific antiviral treatment recommended for acute HBV in the setting of needlestick PEP - HBV generally self-resolves in adults (~90-95% clearance rate).

SCENARIO C: HEPATITIS C VIRUS (HCV)

• Neither immunoglobulin nor antivirals are recommended as PEP after needlestick exposure to HCV.
• The management is monitoring and early treatment if infection occurs.

HCV Post-Exposure Monitoring Protocol (Goldman-Cecil Medicine):

• If HCV RNA becomes detectable at any point - the HCW has been infected.
• Treat immediately with direct-acting antivirals (DAAs) for 8 weeks:
  • Sofosbuvir 400mg + Velpatasvir 100mg (fixed-dose, once daily) - pan-genotypic
  • OR Glecaprevir 100mg + Pibrentasvir 40mg (3 pills once daily) - pan-genotypic
• Treatment of acute HCV is preferred over waiting - it achieves higher cure rates and prevents chronic infection (20-50% would spontaneously clear, but 50-80% will develop chronic HCV if untreated).
• Cure assessment: HCV RNA at 12 and 24 weeks post-treatment (late relapses have been reported).

SCENARIO D: NEEDLE FOUND IN SHARPS CONTAINER / COMPLETELY UNKNOWN SOURCE

• This is a common and challenging scenario.
• No cases of HIV transmission from "found needles" outside healthcare settings in the US have been documented.
• Within healthcare settings, found needles have been implicated in only two cases of transmission over two decades.
• PEP is generally not recommended for low-risk "found needle" scenarios.
• Use shared decision-making considering:
  1. Severity of the injury
  2. Route (percutaneous vs. superficial)
  3. Amount of potentially infectious material present
  4. Epidemiologic likelihood of HIV exposure (setting, patient population)
• If the HCW is very anxious or insists, expert consultation via PEPline (1-888-448-4911) is appropriate.

PART 6: SPECIAL ADDITIONAL ORGANISMS TO CONSIDER

• Syphilis (Treponema pallidum): Baseline RPR/VDRL; can consider single-dose benzathine penicillin 2.4 MU IM if source is high-risk or known syphilis.
• HTLV-I/II: Consider testing in high-prevalence areas; no PEP available.
• Viral hemorrhagic fevers (e.g., Ebola - in relevant settings): Post-exposure prophylaxis should be considered for high-risk exposures in unvaccinated persons (monoclonal antibody treatments; oral ribavirin for Lassa/CCHF); evacuate and manage per institutional/public health protocols.
• CMV, EBV: Generally not transmitted by needlestick in immunocompetent HCWs; no PEP.
• Malaria: Considered in endemic settings if patient had active parasitemia - can treat presumptively.

PART 7: COMPLETE FOLLOW-UP SCHEDULE SUMMARY

PART 8: PSYCHOLOGICAL SUPPORT

• Informed the absolute risk of HIV transmission per needlestick is low (~0.3%).
• Offered counseling or psychological support.
• Reassured about confidentiality of testing and treatment.
• Encouraged to report rather than hide exposures.

PART 9: DOCUMENTATION AND REPORTING

• Complete an incident report per institutional policy.
• In the US, OSHA Bloodborne Pathogen Standards require that exposures be documented and followed.
• In many jurisdictions, needlestick injuries must be reported to occupational health registries.

QUICK DECISION SUMMARY

• 2025 PHS Guidelines (PMC Full Text) - the most current occupational HIV PEP guidelines
• UCSF NCCC PEP Quick Guide (Oct 2025) - updated October 2025 for all three bloodborne pathogens
• National HIV Curriculum - Occupational PEP - comprehensive clinical review
• PEPline (US): 1-888-448-4911 (24/7 expert consultation)

• Goldman-Cecil Medicine International Edition, pp. 3381-3394 (HIV in healthcare workers, management after needlestick)
• Goldman-Cecil Medicine International Edition, p. 1659 (HCV needlestick: no PEP, monitoring + DAA if infected)
• Yamada's Textbook of Gastroenterology, 7th ed., Table 86.8 (HBV post-exposure prophylaxis table)
• Tintinalli's Emergency Medicine, pp. 2419-2421 (Needlestick injuries - risk estimates and management overview)
• 2025 US Public Health Service Guidelines for Occupational HIV Exposure and PEP (PMID/PMC12616222) - published September 2025 in Infection Control and Hospital Epidemiology
• Weber DJ et al., Infect Dis Clin North Am 2026 Jun - Evaluation and Management of Occupational Exposures and PEP [PMID 41820134]

Hepatitis B vs C: Modes of Transmission, Natural History, Outcomes & Mnemonics

SECTION 1: MODES OF SPREAD - HEPATITIS B (HBV)

HBV Transmission Routes (Most to Least Common by Incidence)

SECTION 2: MODES OF SPREAD - HEPATITIS C (HCV)

HCV Transmission Routes (Most to Least Common by Incidence)

SECTION 3: KEY DIFFERENCES IN TRANSMISSION AT A GLANCE

SECTION 4: NATURAL HISTORY - HEPATITIS B

A. Acute HBV Infection Outcomes (Adult-Acquired)

(Robbins & Kumar Basic Pathology - HBV outcomes flow chart)

B. Age-Dependent Chronicity Rate (Critical Concept)

C. Natural History of Chronic HBV (Untreated)

1. Immune Tolerant Phase - High HBV DNA (>10⁸ IU/mL), HBeAg+, normal ALT, minimal inflammation. Lasts decades in perinatally acquired HBV. High risk of transmission.
2. Immune Active / Immune Clearance Phase - Rising ALT, falling HBV DNA, inflammation. Hepatic damage occurs here. HBeAg seroconversion happens.
3. Inactive Carrier Phase - After HBeAg seroconversion; HBeAg negative, anti-HBe positive, low HBV DNA (<2000 IU/mL), normal ALT, minimal histological activity. 70-80% of patients reach this phase.
4. HBeAg-Negative Hepatitis (Reactivation Phase) - HBeAg negative, but active hepatitis due to pre-core or core promoter mutant virus; fluctuating HBV DNA and ALT.

D. Long-Term Complications of Chronic HBV (Untreated)

E. With Treatment (Treated HBV)

• Nucleos(t)ide analogues (entecavir, tenofovir): suppress HBV DNA to undetectable, normalize ALT, reduce cirrhosis risk by ~50-70%, reduce HCC risk by ~40-70%
• HBsAg clearance (functional cure): rare, ~1-3% per year even on treatment; remains the goal
• Treatment does NOT eradicate cccDNA - lifelong suppression is usually needed
• Regression of established cirrhosis is possible with long-term viral suppression
• No curative treatment yet - functional cure (HBsAg clearance) is achievable in a minority

SECTION 5: NATURAL HISTORY - HEPATITIS C

A. Acute HCV Infection Outcomes

B. Natural History of Chronic HCV (Untreated)

C. With Treatment (Treated HCV - DAAs)

• DAAs (sofosbuvir-based, glecaprevir/pibrentasvir) achieve Sustained Virologic Response (SVR) in >95% of patients - effectively a cure
• SVR = HCV RNA undetectable at 12 weeks post-treatment - defined as cure
• After SVR: no further viral transmission, regression of fibrosis/inflammation, significant reduction in HCC risk
• HCC risk after SVR in cirrhotics: drops by ~70%, but residual risk remains (~1-2%/year) - surveillance must continue
• Cirrhosis can partially regress after SVR
• Treatment course: 8 weeks for most patients (including acute HCV); 12 weeks if cirrhotic

SECTION 6: COMPARISON TABLE - OUTCOMES SIDE BY SIDE

SECTION 7: EASY MNEMONICS

MNEMONIC 1: HBV Chronicity by Age - "90-20-5 Rule"

"90 babies, 20 children, 5 adults"

• 90% → neonates/perinatally acquired
• 20-60% → children under 5 (remember as "20")
• <5% → immunocompetent adults

MNEMONIC 2: HBV Acute Outcomes - "65-30-5 Rule" (or use the Robbins diagram above)

"65% Silent, 30% Yellow, 5% Chronic, 0.5% Fail"

• 65% = subclinical/silent (anicteric)
• 30% = icteric hepatitis
• 5-10% = chronic infection (adult)
• 0.1-0.5% = fulminant hepatic failure

MNEMONIC 3: HCV Outcomes - "80-20-20-4 Rule"

"80% don't know, 20% clear it, 20% (of chronic) get cirrhosis, then 4% HCC/yr"

• ~80% = asymptomatic acute infection
• ~20-45% = spontaneous clearance
• 55-85% = chronic infection
• 15-30% = cirrhosis at 20 years
• 2-4%/year = HCC once cirrhotic

MNEMONIC 4: HBV Phases - "IT-IC-IN-RE" (like "Inactive-Reactivate")

IT - IC - IN - RE

• IT = Immune Tolerant (HBV DNA high, ALT normal, no damage - "Tolerating the virus")
• IC = Immune Clearance (fighting the virus - ALT rises, damage occurs)
• IN = INactive Carrier (virus sleeping, low DNA, normal ALT)
• RE = REactivation (HBeAg-neg hepatitis, mutant virus wakes up)

MNEMONIC 5: HBV vs HCV Transmission - "SIPS vs SPIT"

S - Sexual contact I - IV drug use / Injection P - Perinatal (mother-to-child) - #1 globally S - Sharps/blood (occupational, transfusion)

S - Sharps/blood/IVDU - #1 by far P - Percutaneous (needlestick, tattoo) I - Intranasal drug use (shared straws) T - Transfusion (historical, now rare)

MNEMONIC 6: HBV vs HCV - "WHO CLEARS IT?"

"B for BAD at clearing; C for CAN clear"

• HBV (B = BAD at clearing when caught young): Neonates rarely clear it (90% chronic) - the immune system is too immature
• HCV (C = CAN clear sometimes): 15-45% spontaneously clear with an intact immune response

MNEMONIC 7: The "FIVE F's" of Fulminant Hepatitis - Who is at Risk?

Fulminant risk is high when: Five scenarios = HDV + HBV co-infection (most feared), underlying chronic liver disease, HBV + HCV, immunosuppression, pregnancy (Hepatitis E, not B/C)

MNEMONIC 8: Remembering Chronicity Numbers

• HBV (B): 90% perinatal, 5% adult
• HCV (C): 85% (55-85%) of acute HCV becomes chronic

SECTION 8: QUICK VISUAL SUMMARY CARD

                    HBV ACUTE INFECTION
                           ↓
         ┌─────────────────┼────────────────────┐
      ~65% Silent      ~30% Icteric         ~0.5% Fulminant
       (recover)       (mostly recover)     (death/transplant)
                    95-99% resolve
                         5-10% → CHRONIC
                                  ↓
                    ┌─────────────┴──────────────┐
                 70-80%                        20-30%
             Inactive Carrier              Chronic Hepatitis
                    ↓                           ↓
           Spontaneous                    15-40% CIRRHOSIS
           clearance (1-2%/yr)                  ↓
                                         2-3%/yr HCC

---

                    HCV ACUTE INFECTION
                           ↓
              ┌────────────┴───────────────┐
           15-45%                       55-85%
      Spontaneous Clearance         CHRONIC HCV
                                         ↓
                              20 yrs: 15-30% CIRRHOSIS
                                         ↓
                                   2-4%/yr HCC
                            (DAA Treatment = >95% cure)

• Robbins & Kumar Basic Pathology, Fig. 14.9 - HBV outcomes flowchart (diagram reproduced above)
• Harrison's Principles of Internal Medicine, 22nd ed. (2025), pp. 1648-1669 - Complications and sequelae of viral hepatitis
• Mulholland & Greenfield's Surgery, 7th ed., pp. 3881-3907 - HBV/HCV clinical features and epidemiology
• Yamada's Textbook of Gastroenterology, 7th ed. - HBV post-exposure management
• Goldman-Cecil Medicine International Edition - HCV natural history, treatment with DAAs
• WHO Global Hepatitis Report 2024 - 240 million chronic HBV, 1.1 million deaths/year
• PMC11168840 (2024) - "Revisiting the natural history of chronic hepatitis B" - Clin Liver Dis
• WHO Guidelines on Hepatitis B and C Testing (NBK442290) - chronicity rates by age
• PMID 41839199 (2026, Lancet Gastroenterol Hepatol) - Systematic review on natural history of chronic HBV

Comprehensive Clinical Analysis: Complex Neuro-Orbital Case

PART 1: CLINICAL INTERPRETATION - WHAT IS THIS PRESENTATION TELLING US?

Anatomical Decoding of the Presentation

PART 2: DIFFERENTIAL DIAGNOSIS - STRUCTURED AND RANKED

1. Left orbital apex syndrome (CN II-VI affected at orbital apex)
2. Left cavernous sinus thrombosis/involvement (confirmed on CT)
3. Central/supranuclear right facial palsy (cortical involvement)
4. Bilateral cranial neuropathies (voice change, bilateral ear symptoms) = skull base / posterior fossa

Differential Diagnosis - Primary (Most Likely to Least Likely in This Context)

DD1: Rhino-Orbital-Cerebral Mucormycosis (ROCM) - HIGHEST CLINICAL SUSPICION

• Diabetic, non-compliant (immunocompromised host - #1 risk factor)
• Sinusitis (maxillary) as source
• Orbital cellulitis + proptosis + complete ophthalmoplegia + retinal detachment + optic neuritis = orbital apex syndrome (68.25% of ROCM patients with ocular involvement have orbital apex as predominant site)
• Cavernous sinus involvement (CT confirmed)
• Gradual but progressive course (10-15 days)
• Bilateral ear symptoms, voice change = skull base spread

• No palatal eschar - but this is only present in 50% of ROCM within 3 days; absence does NOT exclude diagnosis (Goldman-Cecil Medicine)
• Endoscopy showing only mild edema - Early ROCM can appear as mild mucosal thickening before frank necrosis; edema alone is a recognized early finding. The black eschar is a late sign.
• Amphotericin B already started - if there was any clinical response, this supports fungal etiology

DD2: Septic Cavernous Sinus Thrombosis (CST) - Secondary to Bacterial Sinusitis

• Maxillary sinusitis as source
• Proptosis, chemosis, ophthalmoplegia, vision loss - classic CST features
• CT showing partial cavernous sinus involvement

• Sinusitis is maxillary (CST most commonly follows ethmoidal or sphenoidal sinusitis - >50%)
• The 10-15 day indolent course is more typical of fungal than bacterial (bacterial CST is usually more acute/fulminant)
• No fever mentioned, no septic picture described
• Bilateral ear symptoms, voice change, right central facial palsy = extensive skull base involvement not typical of simple bacterial CST
• Would expect bilateral involvement earlier if bacteria (bilateral in 24-48h via interconnecting sinuses)
• Staphylococcus aureus (70% of septic CST) usually produces rapid deterioration

DD3: Skull Base Malignancy (Nasopharyngeal Carcinoma / Lymphoma / Meningioma) - Must be excluded

• The patient has had headaches for 1-2 years on and off - this is the critical clue pointing to a long-standing process
• Voice change (CN IX/X) + bilateral ear abnormal sensation + right central facial palsy = multiple skull base cranial nerve involvement (IX, X, XII + facial) = extensive skull base infiltration
• The history of 1-2 years of headache cannot be explained by an acute fungal infection
• Nasopharyngeal carcinoma (NPC) with skull base invasion causes: CN V2 (cheek/palate numbness), CN VI (abducens), recurrent ear symptoms, CST, carotid involvement - exactly what is seen here
• Lymphoma can cause cavernous sinus thrombosis as an aseptic cause
• Meningioma at the sphenoid wing or cavernous sinus can produce all these features slowly
• The "partial cavernous sinus" appearance on CT could represent tumor infiltration, not thrombosis

DD4: Orbital Cellulitis (Postseptal) with Secondary CST

• Ophthalmology has made this diagnosis
• Correct as far as the orbital signs go, but orbital cellulitis is a complication, not the primary etiology
• The question is: what caused the orbital cellulitis? (Fungal? Bacterial? Spread from sinus? Tumor?)
• Orbital cellulitis alone does not explain: right central facial palsy, voice change, bilateral ear symptoms

DD5: Tolosa-Hunt Syndrome

• Painful ophthalmoplegia due to granulomatous inflammation of cavernous sinus/superior orbital fissure
• Can cause CN III, IV, VI, V1 deficits with pain
• Against: vision loss with retinal detachment, systemic risk factors for infection/malignancy, sinusitis
• Treatment: steroids (would be dangerous if fungal is the etiology - potentially fatal)

DD6: Carotid-Cavernous Fistula (CCF)

• Can cause proptosis, chemosis, ophthalmoplegia, IOP elevation
• Usually traumatic (75%) or spontaneous (older hypertensive women - matches this patient's demographics)
• The CT note of "partial cavernous anastomosis" - this phrase is key: could this actually mean a carotid-cavernous fistula with arterialization of the cavernous sinus?
• Kanski's Clinical Ophthalmology specifically notes indirect CCF in "middle-aged hypertensive women" as a cause
• This needs urgent clarification on imaging

DD7: Tolosa-Hunt Syndrome / Idiopathic Orbital Inflammatory Pseudotumor

DD8: Wegener's Granulomatosis (GPA) / Sarcoidosis

• Can cause orbital apex syndrome with sinusitis
• Rosen's Emergency Medicine notes these as causes of orbital inflammatory pseudotumor
• Should be in the workup if infectious/malignant causes excluded

PART 3: THE KEY DIAGNOSTIC CHALLENGE - CST vs ORBITAL APEX SYNDROME vs MALIGNANCY

Understanding the Anatomical Relationship

   CAVERNOUS SINUS contains:         ORBITAL APEX contains:
   CN III (oculomotor)                CN II (optic nerve) ← + in this patient
   CN IV (trochlear)                  CN III, IV, VI ← all affected
   CN V1 (ophthalmic)                CN V1
   CN V2 (maxillary)                 Superior ophthalmic vein
   CN VI (abducens)
   Internal carotid artery
   Sympathetic plexus

What the Current Imaging DOESN'T Tell You

1. Extent of cavernous sinus thrombosis (MRI + MRV is gold standard)
2. Differentiating fungal tissue necrosis from bacterial infection from tumor
3. Perineural spread (better on MRI)
4. "Black turbinate sign" (early ROCM sign - only on MRI)
5. Internal carotid artery involvement/narrowing (catastrophic in ROCM)
6. Intracranial extension to brain parenchyma
7. Nasopharyngeal/skull base mass lesion

PART 4: STEP-BY-STEP INVESTIGATION PROTOCOL

URGENT (Do Immediately - Within Hours)

PART 5: CRITICAL DIAGNOSTIC DECISION TREE

          PATIENT PRESENTATION
                  ↓
    Left orbital apex syndrome +
    Left cavernous sinus (CT) +
    Right central facial palsy +
    Bilateral skull base cranial neuropathies
    Maxillary sinusitis + Diabetic
                  ↓
         ┌────────┴────────┐
      FUNGAL              NON-FUNGAL
      (ROCM)              Causes
         ↓                    ↓
   Tissue biopsy         ┌────┴────┐
   KOH + HPE           MALIGNANT  SEPTIC
   MRI features        (NPC/       (Bacterial
   - black turbinate   Lymphoma/   CST/
     sign              Meningioma) Orbital
   - ICA               ↓           cellulitis)
     narrowing      Nasopharyngo-    ↓
   - no ring          scopy       Blood
     enhancement     CT guided    cultures +
   (necrosis)        biopsy       Sensitivities
                     PET scan        ↓
                     Skull base   Antibiotic
                     MRI+DWI      adjustment
                        ↓
                   VASCULAR
                   (CCF / ICA
                   aneurysm)
                        ↓
                    DSA / MRA
                   mandatory

PART 6: THE "PARTIAL CAVERNOUS ANASTOMOSIS" ON CT - WHAT DOES THIS MEAN?

1. Partial cavernous sinus thrombosis - thrombus not completely occluding the sinus (partial filling defect on contrast CT)
2. Alternatively: the report may describe a "carotid-cavernous fistula" or abnormal vascular communication - especially important given this patient is a hypertensive middle-aged woman (spontaneous indirect CCF)

PART 7: CURRENT MANAGEMENT - What to Do Right Now

Immediate (Active Now)

• Liposomal Amphotericin B (L-AmB) is preferred over conventional Amphotericin B deoxycholate - same efficacy with significantly less nephrotoxicity
• Dose for ROCM: 5-10 mg/kg/day IV of liposomal formulation
• If on conventional amphotericin: SWITCH to liposomal immediately, especially important given diabetic nephropathy risk
• Duration: minimum 4-6 weeks, often extended; treatment continues until clinical response and until surgical debridement is complete

• Aggressive insulin therapy to achieve euglycemia (target glucose 140-180 mg/dL)
• Uncontrolled diabetes (especially DKA with acidemia) directly promotes mucormycosis growth (iron release from transferrin in acidic pH; impaired neutrophil function)
• Metabolic control is as important as antifungal therapy

• IV nafcillin/oxacillin + third-generation cephalosporin (covers Staph aureus + gram-negatives)
• Or vancomycin if MRSA prevalent in your institution
• Add metronidazole if dental source suspected
• This should run concurrently with antifungals until bacterial etiology excluded

• Anticoagulation (IV heparin then warfarin) may be considered for septic CST after ruling out intracranial hemorrhage on imaging
• However, in ROCM with cavernous sinus involvement + ICA at risk, anticoagulation is potentially dangerous
• Do NOT start anticoagulation until MRI/MRA has excluded ICA involvement and intracranial hemorrhage
• The decision must involve neurosurgery + infectious disease + hematology

Surgical Management - Critical Decision

Step-by-Step Protocol Going Forward

STEP 1 (Hours 0-6):
□ Emergency MRI brain/orbits/skull base + MRV + MRA
□ Upgrade to Liposomal AmB 5-10mg/kg/day if not already done
□ Start IV antibiotics (covers bacterial CST simultaneously)
□ Strict glycemic control with insulin infusion
□ Urgent ophthalmology: B-scan, IOP, fundoscopy
□ Full blood panel: CBC, renal/liver, coagulation, D-dimer, cultures

STEP 2 (Within 24 hours):
□ ENT under GA: rigid endoscopy + deep biopsies
□ KOH/Calcofluor white stain (SAME DAY result)
□ Frozen section histopathology (same day)
□ Nasopharyngoscopy (exclude NPC)
□ β-D-glucan and galactomannan (negative in mucor = important)
□ Thrombophilia screen, ANA/ANCA, ACE
□ HIV test

STEP 3 (Interpret results at 24-48 hours):
□ If biopsy = ROCM confirmed:
   - Surgical debridement (FESS ± orbital exenteration)
   - Add posaconazole 300mg OD as combination/step-down therapy
   - Continue L-AmB for 4-6+ weeks
   - Repeat MRI at 2 weeks

□ If biopsy = Aspergillus:
   - Switch to voriconazole (first-line for Aspergillus)
   - Different surgical strategy

□ If biopsy = negative / no fungi found:
   - URGENT nasopharyngoscopy + skull base MRI +
     PET-CT to exclude malignancy
   - Neurology/neurosurgery consult
   - Consider CT-guided skull base biopsy

□ If MRI shows CCF:
   - Urgent interventional neuroradiology consult
   - DSA for definitive diagnosis and embolization

STEP 4 (Ongoing monitoring):
□ Daily renal function (amphotericin nephrotoxicity)
□ Potassium/magnesium replacement (amphotericin causes hypokalemia/hypomagnesemia)
□ Serial MRI every 2-4 weeks to monitor treatment response
□ Ophthalmology: visual function monitoring (though left eye lost)
□ Right eye protection - at risk if disease spreads bilaterally

PART 8: Why the Current Diagnosis is Incomplete - The Critical Thinking

The 5 Unresolved Questions in This Case

• Drug resistance (rare in mucor but possible)
• Inadequate dosing or wrong formulation (conventional vs. liposomal)
• It is NOT mucormycosis - the underlying etiology is something else (malignancy, CCF, non-fungal infection)

PART 9: MDT (Multidisciplinary Team) That Must Be Involved

PART 10: PROGNOSIS AND RED FLAGS TO WATCH FOR

• Goldman-Cecil Medicine International Edition - Rhinocerebral Mucormycosis section (pp. 4117-4195): diagnosis, radiology, histopathology, treatment
• Rosen's Emergency Medicine - Orbital Apex Syndrome and CST differential (pp. 3819-3841)
• Kanski's Clinical Ophthalmology, 10th ed. - Cavernous sinus thrombosis (pp. 5868-5872); Carotid-cavernous fistula
• Scott-Brown's Otorhinolaryngology, Vol 2 - Cavernous sinus thrombosis: features, imaging, treatment (pp. 4318-4349)
• KJ Lee's Essential Otolaryngology - Orbital apex syndrome definition and nerve anatomy
• Honavar SG. "Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis" - Indian J Ophthalmol 2021; PMC8302268
• Merck Manual Professional Edition - Cavernous Sinus Thrombosis (updated April 2026)
• PMID 41866895 (2026): Successful ROCM outcome in poorly controlled diabetes - Perm J
• PMID 41575678 (2026): Multicenter ROCM outcomes, retromucor study - Eur J Clin Microbiol Infect Dis